The Fab Region of IgG Impairs the Internalization Pathway of FcRn Upon Fc Engagement
Overview
Authors
Affiliations
Binding to the neonatal Fc receptor (FcRn) extends serum half-life of IgG, and antagonizing this interaction is a promising therapeutic approach in IgG-mediated autoimmune diseases. Fc-MST-HN, designed for enhanced FcRn binding capacity, has not been evaluated in the context of a full-length antibody, and the structural properties of the attached Fab regions might affect the FcRn-mediated intracellular trafficking pathway. Here we present a comprehensive comparative analysis of the IgG salvage pathway between two full-size IgG1 variants, containing wild type and MST-HN Fc fragments, and their Fc-only counterparts. We find no evidence of Fab-regions affecting FcRn binding in cell-free assays, however, cellular assays show impaired binding of full-size IgG to FcRn, which translates into improved intracellular FcRn occupancy and intracellular accumulation of Fc-MST-HN compared to full size IgG1-MST-HN. The crystal structure of Fc-MST-HN in complex with FcRn provides a plausible explanation why the Fab disrupts the interaction only in the context of membrane-associated FcRn. Importantly, we find that Fc-MST-HN outperforms full-size IgG1-MST-HN in reducing IgG levels in cynomolgus monkeys. Collectively, our findings identify the cellular membrane context as a critical factor in FcRn biology and therapeutic targeting.
SynBioNanoDesign: pioneering targeted drug delivery with engineered nanomaterials.
Cai Q, Guo R, Chen D, Deng Z, Gao J J Nanobiotechnology. 2025; 23(1):178.
PMID: 40050980 PMC: 11884119. DOI: 10.1186/s12951-025-03254-9.
Nipocalimab, an immunoselective FcRn blocker that lowers IgG and has unique molecular properties.
Seth N, Xu R, DuPrie M, Choudhury A, Sihapong S, Tyler S MAbs. 2025; 17(1):2461191.
PMID: 39936406 PMC: 11834464. DOI: 10.1080/19420862.2025.2461191.
Zakrzewicz A, Vanderheyden K, Galaly Y, Feldhoff S, Sips M, Brinkhaus M Front Immunol. 2024; 15:1473637.
PMID: 39450168 PMC: 11499148. DOI: 10.3389/fimmu.2024.1473637.
Hurst S, Flossdorf D, Koralagamage Don R, Pernthaner A Innate Immun. 2024; 30(5):96-118.
PMID: 39252173 PMC: 11418599. DOI: 10.1177/17534259241269724.
evaluation of the role of Fab glycosylation in cetuximab antibody dynamics.
Saporiti S, Bianchi D, Ben Mariem O, Rossi M, Guerrini U, Eberini I Front Immunol. 2024; 15:1429600.
PMID: 39185413 PMC: 11342397. DOI: 10.3389/fimmu.2024.1429600.